Background Cardiovascular (CV) morbidity and mortality are significantly greater in Systemic Lupus Erythematosus (SLE) patients than in the general population. Acetylsalicylic acid (ASA) is known to be associated with a decrease in the incidence of CV events in high-risk patients from general population .
Objectives We previously investigated ASA efficacy as primary prophylaxis in 167 SLE patients followed for 7 patient-years . Here, we report data collected in 189 patients followed for 8,2 patient-years.
Methods SLE patients consecutively admitted to a tertiary center, who, at admission, satisfied 1992 ACR and/or 2012 SLICC classification criteria for SLE and had not experienced any CV event, were enrolled into the study. Low-dose ASA (100 mg/day) was prescribed to each patient at first visit. Fourteen patients (7%) refused to take it. At each 6-monthly visit, ASA side effects, ASA discontinuation and occurred CV events were recorded.
Results 189 consecutive SLE patients were followed-up for a median of 8 years (range 1–15). Among them, 164 regularly took the medication (ASA-treated) and 25 refused to take or discontinued it (non-ASA-treated patients). Six CV events occurred in the 164 ASA-treated (4.2/1000 person-years), 4 in the 25 non-ASA-treated patients (25.4/1000 person-years) (p=0.003). No relevant side effect related to ASA treatment was recorded.
Conclusions Present data further support the role of ASA in the primary prophylaxis of CV events in SLE patients.
Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012;141
Iudici M, Fasano S, Gabriele Falcone L, et al. Low-dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Systemic Lupus Erythematosus: A Long-Term Retrospective Cohort Study. Rheumatology (Oxford) Submitted for publication.
Disclosure of Interest None declared